Horrobin, D.F.; Manku, M.S.; Oka, M.; Cunnane, S.C.
The role of a prostaglandin E1 deficiency in schizophrenia: interactions with dopamine and opiates
In: Hemmings, G. (Ed.) Biochemistry of scizophrenia and addiction, MTP Press Ltd. 1980: 3-18.


There is evidence for a prostaglandin (PG) E1 deficiency in schizophrenia. Dopamine is able to antagonize some of the effects of PGE1 on excitable tissues and the fundamental problem may therefore be an elevated dopamine:PGE1 ratio. Schizophrenia should therefore be made worse by factors which raise this ratio and alleviated by factors which lower it. Opiates and various dietary deficiencies may lower PGE1 formation whereas prolactin and melatonin may enhance it. Most of the existing antischizophrenic drugs may function because they have three separate actions which will tend to lower the effective dopamine/PGE1 ratio. They block dopamine receptors, they enhance prolactin secretion and they enhance melatonin secretion. This concept leads to new therapeutic strategies which seem worthy of trial.

All copyrights acknowledged

© Peter Lapinskas 1999-2012 Email Peter Lapinskas Last updated: 3 July 2012

Home      Services      Background      Publications      Resources      Contact